TRML TOURMALINE BIO INC

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:

Guggenheim Securities SMID Cap Biotech Conference, New York

Fireside Chat

Wednesday, February 5, 2025, at 1:30 pm ET

A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at .

About Tourmaline Bio

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit or follow us on or .

Media Contact

Scient PR

Sarah Mishek

  

Investor Contact

Meru Advisors

Lee M. Stern



EN
27/01/2025

Underlying

TRMLTOURMALINE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TOURMALINE BIO INC

Laura Chico
  • Laura Chico
TRML TOURMALINE BIO INC
10/31/25 October 31, 2025 1 EN
Wedbush Research
  • Wedbush Research
LEN LENNAR CORPORATION CLASS A
AAPL APPLE INC.
IDYA IDEAYA BIOSCIENCES
TRML TOURMALINE BIO INC
CBIO CRESCENT BIOPHARMA INC.
09/09/25 September 9, 2025 1 EN
Laura Chico
  • Laura Chico
TRML TOURMALINE BIO INC
09/09/25 September 9, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG – Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases – – Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions – NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”)...

September 9, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Tria...

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress – Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity including lipoprotein(a), fibrinogen, and serum amyloid A – NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage c...

August 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch